Stereotactic ablative radiotherapy (SABR) for patients with metachronous extracranial oligometastatic cancer (all ages)

Document first published:
Page updated:
Topic:
Publication type:
,

SABR will be available as a treatment option through routine commissioning for patients (all ages) with controlled primary cancer presenting with up to three extracranial metachronous oligometastases which manifest after a disease-free interval following primary treatment of at least 6 months, in line with the criteria set out in this document.

Document

Clinical Panel Report

Clinical Panel Report

  • PDF
  • 132 KB
  • 2 pages

Document

Consultation Report

Consultation Report

  • PDF
  • 53 KB
  • 2 pages

Document

CPAG Summary Report

CPAG Summary Report

  • PDF
  • 60 KB
  • 6 pages

Document

Evidence Review

Evidence Review

  • PDF
  • 1 MB
  • 80 pages